176 related articles for article (PubMed ID: 26504364)
1. 25-OH Vitamin D and Interleukin-8: Emerging Biomarkers in Cutaneous Melanoma Development and Progression.
Ene CD; Anghel AE; Neagu M; Nicolae I
Mediators Inflamm; 2015; 2015():904876. PubMed ID: 26504364
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma.
Timerman D; McEnery-Stonelake M; Joyce CJ; Nambudiri VE; Hodi FS; Claus EB; Ibrahim N; Lin JY
Oncotarget; 2017 Jan; 8(4):6873-6882. PubMed ID: 28036288
[TBL] [Abstract][Full Text] [Related]
3. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: A pilot study.
Lim A; Shayan R; Varigos G
Australas J Dermatol; 2018 Aug; 59(3):182-187. PubMed ID: 28332194
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D deficiency at melanoma diagnosis is associated with higher Breslow thickness.
Wyatt C; Lucas RM; Hurst C; Kimlin MG
PLoS One; 2015; 10(5):e0126394. PubMed ID: 25970336
[TBL] [Abstract][Full Text] [Related]
5. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population.
Li C; Liu J; Jiang L; Xu J; Ren A; Lin Y; Yao G
Medicine (Baltimore); 2021 Feb; 100(8):e24840. PubMed ID: 33663104
[TBL] [Abstract][Full Text] [Related]
6. The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate.
Davies JR; Chang YM; Snowden H; Chan M; Leake S; Karpavicius B; Haynes S; Kukalizch K; Randerson-Moor J; Elliott F; Barth J; Kanetsky PA; Harland M; Bishop DT; Barrett JH; Newton-Bishop JA
Cancer Causes Control; 2011 Oct; 22(10):1471-82. PubMed ID: 21853245
[TBL] [Abstract][Full Text] [Related]
7. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
Franzke A; Probst-Kepper M; Buer J; Duensing S; Hoffmann R; Wittke F; Volkenandt M; Ganser A; Atzpodien J
Br J Cancer; 1998 Jul; 78(1):40-5. PubMed ID: 9662248
[TBL] [Abstract][Full Text] [Related]
8. Effects of vitamin D on disease activity and serum interleukin-6 in rheumatoid arthritis.
Gopal K; Thevarajah M; Ng CM; Raja J
Int J Rheum Dis; 2019 May; 22(5):834-841. PubMed ID: 30729713
[TBL] [Abstract][Full Text] [Related]
9. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients.
Nürnberg B; Gräber S; Gärtner B; Geisel J; Pföhler C; Schadendorf D; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3669-74. PubMed ID: 19667163
[TBL] [Abstract][Full Text] [Related]
10. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
Desch A; Gebhardt C; Utikal J; Schneider SW
Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
12. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
13. Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona.
Ogbah Z; Visa L; Badenas C; Ríos J; Puig-Butille JA; Bonifaci N; Guino E; Augé JM; Kolm I; Carrera C; Pujana MÁ; Malvehy J; Puig S
BMC Med Genet; 2013 Feb; 14():26. PubMed ID: 23413917
[TBL] [Abstract][Full Text] [Related]
14. Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma.
Gao D; Ma X
Panminerva Med; 2017 Dec; 59(4):332-337. PubMed ID: 27309261
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
De Smedt J; Van Kelst S; Boecxstaens V; Stas M; Bogaerts K; Vanderschueren D; Aura C; Vandenberghe K; Lambrechts D; Wolter P; Bechter O; Nikkels A; Strobbe T; Emri G; Marasigan V; Garmyn M
BMC Cancer; 2017 Aug; 17(1):562. PubMed ID: 28835228
[TBL] [Abstract][Full Text] [Related]
16. Association between 25-hydroxyvitamin D and inflammatory biomarker levels in a cross-sectional population-based study, São Paulo, Brazil.
de Souza WN; Norde MM; Oki É; Rogero MM; Marchioni DM; Fisberg RM; Martini LA
Nutr Res; 2016 Jan; 36(1):1-8. PubMed ID: 26773775
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
[TBL] [Abstract][Full Text] [Related]
18. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study.
Soubrane C; Rixe O; Meric JB; Khayat D; Mouawad R
Melanoma Res; 2005 Jun; 15(3):199-204. PubMed ID: 15917702
[TBL] [Abstract][Full Text] [Related]
20. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
Ugurel S; Rappl G; Tilgen W; Reinhold U
J Clin Oncol; 2001 Jan; 19(2):577-83. PubMed ID: 11208853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
